Pakistan Journal of Ophthalmology Vol. 31, No. 3, Jul – Sep, 2015      124 

Original Article 

 

Effect of Topical Latanoprost 0.005% Drops 
on Central Corneal Thickness in Patients 
with Primary Open Angle Glaucoma 
 
Akhunzada Mohammad Aftab, Mubashir Rehman, Sher Akbar Khan, Farooq Khan, Awais Rauf 

 
Pak J Ophthalmol 2014, Vol. 30, No. 3 

 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .  
See end of article for 
authors affiliations 
 
…..……………………….. 
 
Correspondence to: 
Mubashir Rehman 
Medical Officer Department of 
Ophthalmology, Lady Reading 
Hospital, Peshawar 
Email:dr_mubashir@yahoo.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
…..……………………….. 

Purpose: To determine the effect of topical 0.005% Latanoprost on central 
corneal thickness in patients with Primary Open Angle Glaucoma. 

Material and Methods: This study was conducted at Eye “A” unit, Khyber 
Teaching Hospital, Peshawar. Total sample size was 139 eyes. Baseline IOP 
measurement was taken with Goldman applanation tonometer. Central corneal 
thickness was measured by a single trained doctor using the Quantel

® 

Pachymeter. All patients were prescribed Latanoprost 0.005% eye drops once 
daily in the evening. Follow up was at 2 weeks and 8 weeks. 

Results: Mean age was 52 years with SD ±2.71. Sixty nine (55%) patients were 
male and 56 (45%) were female.  Mean difference between baseline CCT and 
CCT after eight weeks was 4% as mean baseline CCT level was 538 μm with 
SD ± 1.87 and mean CCT level after 8 weeks was 534 μmwith SD ±2.12. 
Efficacy of effect of Latanoprost on central corneal thickness of patients with 
primary open angle glaucoma was analyzed as Latanoprost was effective in 
reducing CCT in 104 eyes (75%) of 94 patients and was not effective in 35 eyes 
(25%) of 31 patients. 

Conclusion: Our study concludes that topical 0.005% Latanoprost eye drops 
reduces the central corneal thickness, so latanoprost therapy requires careful 
monitoring while treating patients with primary open angle glaucoma. However 
this reduction in CCT was not ≥ 25 µm from base line reading which is not 
significant enough and hence did not have an effect on IOP reading using 
Goldman applanation tonometer. 

Key words: Latanoprost, central corneal thickness, Primary Open Angle 
Glaucoma. 

 
Glaucoma has become an important cause of 
blindness worldwide especially in the aging 
age group. New statistics gathered by the 

WHO show that glaucoma is now the second leading 
cause of blindness globally.1 It is the fourth 
commonest cause of Blindness in Pakistan.2 Glaucoma 
affects about 60 million people globally and is the 
causative factor of 12% of global blindness.3, 4 More 
than 3 million people are bilaterally blind from POAG 
worldwide, and more than 2 million people will 
develop POAG each year.5 

 Intra ocular Pressure (IOP) measurement is one of 
the key steps in diagnosis and monitoring and the 
gold standard is Goldman Applanation Tonometry 
(GAT). A linear correlation between Central Corneal 
Thickness (CCT) and IOP measured by Goldman 
Applanation tonometer has been described by several 
groups suggesting that Goldman Applanation 
Tonometry results in under estimation in thin corneas 
and overestimation in thick corneas.6 

 To prevent glaucoma progression and to preserve 
vision, mean intraocular pressure should be decreased 

G 



AKHUNZADA MOHAMMAD AFTAB, et al 

125      Vol. 31, No. 3, Jul – Sep, 2015 Pakistan Journal of Ophthalmology 

to a patient dependent target pressure.7 The current 
treatment modalities for glaucoma include medical, 
laser (usually trabeculoplasty) and surgical (usually 
trabeculectomy).8 

 Regarding medical therapy Prostaglandin 
analogues are more cost-effective than beta-blockers 
for any stage of POAG.9 Latanoprost is a 
prostaglandin F2α analogue. Latanoprost 0.005% 
decreases IOP by increasing outflow of aqueous 
humor through uveoscleral pathways.8 Common side 
effects include conjunctival irritation and hyperemia, 
eyelash changes (increased length, thickness, 
pigmentation, and number of lashes), eyelid skin 
darkening, intraocular inflammation (iritis / uveitis), 
iris pigmentation changes, and macular edema, 
including cystoid macular edema.8 

 Evaluation of corneal thickness have been done in 
several populations. Comparison among different 
populations is difficult due to different measurement 
techniques and missing data. Aghaian et al. evaluated 
differences in central corneal thickness, and showed 
that the CCT of Japanese was significantly lower than 
that of Caucasians, Filipinos, Chinese, and Hispanics, 
and greater than that of African Americans., African 
Americans have thinner corneas compared to white 
subjects. 10 

 In a study conducted on Pakistani population the 
mean (SD) CCT measurements were 531.08 +/- 33.37) 
and 531.29 +/- 33.33 micrometers in the right and left 
eyes respectively and were not significantly different 
from each other.11 

 Since no study has been done to look into the 
effects of topical latanoprost therapy on CCT in our 
population, this study will help to prove or disprove 
effect of topical latanoprost therapy on central corneal 
thickness. If found to cause reduction, it would be 
interesting to see whether this decrease in CCT 
significantly affects the IOP readings done by 
Goldman Applanation Tonometer. It would also prove 
beneficial in determining whether serial CCT 
measurement should be a part of monitoring effects of 
Latanoprost therapy. 

 
Material and Methods 

It was a descriptive Cross Sectional Study conducted 
at department of Ophthalmology, Eye “A” Unit 
Khyber Teaching Hospital Peshawar from April 2013 
to October 2013. The total sample size was 139 eyes. 
Sample size was calculated by WHO software for 
sample size calculation using 77.10% proportion of 

decrease in CCT and 95% confidence interval and a 7% 
margin of error. Before starting study, approval was 
taken from hospital’s ethical committee. 

 Patients were selected from outpatient 
department, department of Ophthalmology, Khyber 
Teaching Hospital, Peshawar. All newly diagnosed 
primary open angle glaucoma patients from either 
gender within 20-60 years age group were selected. 
Patients in whom Prostaglandin analogues are 
contraindicated e.g. patients with known allergy to 
prostaglandin analogues, patients with uveitis and 
other ocular inflammatory conditions, patients who 
require multiple drug therapy and patients with 
previous ocular surgery or corneal refractive surgery 
were excluded from the study. 

 Written informed consent was taken from the 
patient. Detailed history was taken followed by 
complete examination including assessment of best 
corrected visual acuity (BCVA), anterior segment 
examination with slit – lamp, baseline IOP 
measurement with Goldman applanation tonometer 
and fundus examination with 90 D lens. Humphrey 
Standard Perimetry was performed. 

 Central corneal thickness was measured in all 
patients by a single trained doctor using the Quantel® 

Pachymeter. The mean of 3 measurements was taken 
for analysis. All patients were prescribed Latanoprost 
0.005% eye drops once daily in the evening. Patients 
were advised to come for follow up at 2 weeks and 8 
weeks. Repeated Central corneal thickness readings 
were taken after 8 weeks by the same method as 
discussed above. CCT measurement was performed in 
the morning to avoid any possible alteration due to 
day – time fluctuations. Those patients who develop 
drug side effects and those who don’t come for follow 
up were omitted from the study. 

 Latanoprost will be said to be efficacious in 
causing change in CCT if a difference in CCT was 
observed after 8 weeks of initiation of therapy 
compared to baseline value of CCT. This change in 
CCT would be considered significant if it was ≥25µ as 
correction factor need to be applied then. 

 SPSS version 20.0 was used for analysis of data. 
Quantitative variables include age and CCT (Base line 
and after 8 weeks); and qualitative variables include 
gender and involvement of eye. Mean ± standard 
deviation was calculated for quantitative variables; 
percentage and proportion was calculated for 
qualitative variables. Efficacy was stratified among 
age, gender and baseline CCT to see effect modifiers. 



EFFECT OF TOPICAL LATANOPROST 0.005% DROPS ON CENTRAL CORNEAL THICKNESS IN PATIENTS WITH POAG 

Pakistan Journal of Ophthalmology Vol. 31, No. 3, Jul – Sep, 2015      126 

Table 1:  Base Line CCT (n = 139 eyes). 
 

Base line CCT 
Frequency 

Total 
Right eye Left eye Both eyes 

<  500 μm 5 (4%) 5 (4%) 3 (2%) 13 (10%) 

500  - 525 μm 15 (11%) 15 (11%) 9 (6%) 39 (28%) 

525  - 555 μm 22 (16%) 23 (17%) 13 (9%) 58 (42%) 

555  - 570 μm 14 (10%) 12 (8%) 3 (2%) 29 (20%) 

Total 56 (40%) 55 (40%) 28 (20%) 139 (100%) 

 

Mean baseline CCT level was 538 μm with SD ± 1.87 

 
Table 2:  CCT at Eight Weeks (n = 139 eyes). 
 

CCT at Eight Weeks 
Frequency 

Total 
Right eye Left eye Both eyes 

< 500 μm 6 (4%) 7 (5%) 4 (3%) 17 (12%) 

500 -525 μm 19 (11%) 17 (11%) 6 (6%) 42 (30%) 

525 -555 μm 20 (14%) 19 (14%) 16 (12%) 55 (40%) 

555 -570 μm 10 (7%) 9 (7%) 6 (4%) 25 (18%) 

Total 56 (40%) 55 (40%) 28 (20%) 139 (100%) 
 

Mean CCT level after 8 weeks was 534 μm with SD ± 2.12 

 
Table 3: Comparison of Base Line CCT and CCT at 

Eight Weeks. 
 

 
Baseline 

CCT 
CCT at 8 
Weeks 

Mean  538 534 

Standard deviation 1.87 2.12 

 

T- test was applied in which P value was 0.0001 

 
RESULTS 

A total of 139 eyes of 125 patients were observed to 
determine the effect of topical 0.005% Latanoprost on 
central corneal thickness in patients with Primary 
Open Angle Glaucoma and the results were analyzes 

as: Age distribution among 125 patients (139 eyes), 
was analyzed as 2(2%) patients were in age range 20 – 
30 years, 5(4%) patients were in age range 31 – 40 
years, 30 (24%) patients were in age range 41 – 50 
years and 88 (70%) patients were in age range 51 – 60 
years. Mean age was 52 years with SD ± 2.71. 

 Gender distribution among 125 patients was 
analyzed as 69 (55%) patients were male while 
56(45%) patients were female. 

 Involvement of eye among 125 patients was 
analyzed as 56 (45%) patients had right eye affected, 
55 (44%) patients had left eye affected and 14 (11%) 
patients had both eyes (14 × 2 = 28 eyes) affected. 

 Base line CCT among 139 eyes was analyzed as 13 
(10%) eyes had CCT level < 500 μm, 39 (28%) eyes had



AKHUNZADA MOHAMMAD AFTAB, et al 

127      Vol. 31, No. 3, Jul – Sep, 2015 Pakistan Journal of Ophthalmology 

Table 4:  Efficacy and Stratification with Involvement of Eye (n = 139 eyes). 
 

Efficacy 
Involvement of eye 

Total 
Right eye Left eye Both eyes 

Yes 42 (30%) 42 (30%) 20 (15%) 104 (75%) 

No 14 (10%) 13 (9%)  8 (6%) 35 (25%) 

Total 56 (40%) 55 (40%) 28 (20%) 139 (100%) 

 

Chi square test was applied in which p value was 0.032 

 
CCT level ranged from 500 – 525 μm, 58 (42%) eyes 
had CCT level ranged from 525 – 555 μm and 29 (20%) 
eyes had CCT level ranged from 555 – 570 μm. Mean 
CCT level was 538 μm with SD ± 1.87 (as shown in 
Table 1). 

 CCT at eight weeks among 139 eyes was analyzed 
as 17 (12%) eyes had CCT level < 500 μm, 42 (30%) 
eyes had CCT level ranged from 500 – 525 μm, 55 
(40%) eyes had CCT level ranged from 525 – 555 μm 
and 25 (18%) eyes had CCT level ranged from 555 – 
570 μm. Mean CCT level was 534 μm with SD ± 2.12 
(as shown in Table 2). 

 Mean difference between baseline CCT and CCT 
after eight weeks was 4% as mean baseline CCT level 

 

Table 5: Efficacy and Stratification with Gender (n = 
139 eyes). 

 

Efficacy 
Gender 

Total 
Male Female 

Yes 56(40%) 48(35%) 104(75%) 

No 20(15%) 15(10%) 35(25%) 

Total 76(55%) 63(45%) 139(100%) 

 

Chi square test was applied in which p value was 
0.047 

 
Table 6:  Efficacy and Stratification with Age Distribution (n = 125 patients). 
 

Efficacy 
Age distribution 

Total 
20 – 30 years 31 – 40 years 41 – 50 years 51 – 60 years 

   Yes 1 (1%) 5 (4%) 19 (15%) 69 (55%) 94 (75%) 

   No 1 (1%) 1 (1%) 13 (10%) 16 (13%) 31 (25%) 

   Total 2 (2%) 6 (5%) 32 (25%) 85 (68%) 125 (100%) 
 

Chi square test was applied in which p value was 0.021 

 
was 538 μm with SD ±1.87 and mean CCT level after 8 
weeks was 534 μm with SD ±2.12.  P value has been 
calculated for pre-treatment and post-treatment CCT 
using T-test and is found to be less than 0.0001. By 
conventional criteria this difference is considered to be 
extremely statistically significant (Table 3). 

 Efficacy of Latanoprost in causing a reduction of 
central corneal thickness of patients with primary 

open angle glaucoma among 139 eyes was analyzed as 
Latanoprost was effective in reducing CCT of 104 
(75%) eyes and in 35(25%) eyes, there was no change 
in CCT (as shown in Table 4). 

 Stratification of efficacy of Latanoprost in causing  
CCT reduction with involvement of eye was analyzed 
as in 104 effective cases of latanoprost therapy, 42 
patients had right eye affected, 42 patients had left eye 



EFFECT OF TOPICAL LATANOPROST 0.005% DROPS ON CENTRAL CORNEAL THICKNESS IN PATIENTS WITH POAG 

Pakistan Journal of Ophthalmology Vol. 31, No. 3, Jul – Sep, 2015      128 

affected and 20 patients had both eyes affected (As 
shown in Table 4). 

 Stratification of efficacy of Latanoprost causing 
reduction of CCT with gender distribution was 
analyzed as in 104 effective cases of latanoprost, 56 
eyes belonged to males, and 48 eyes belonged to 
females (As shown in Table 5). 

 Stratification of efficacy of Latanoprost causing 
reduction of CCT with age distribution was analyzed 
as in 94 effective cases of latanoprost (104 eyes), 1 
patient was in age rage 20 – 30 years, 5 patients were 
in age rage 31 – 40 years, 19 patients were in age rage 
41 – 50 years and 69 patients were in age rage 51 – 60 
years (As shown in Table 6). 

 
DISCUSSION 

Open angle glaucoma is silent killer of vision. It is 
slowly progressive and remains asymptomatic until it 
is very advanced and severe and irreversible damage 
has usually occurred in one or both eyes. It is the 
second leading cause of blindness worldwide.12 

 There are a number of risk factors for glaucoma 
but currently IOP is the only modifiable risk factor 
that can be used to prevent progressive optic 
neuropathy. The Early – Manifest Glaucoma 
Treatment Study showed that IOP reduction by at 
least 25% reduced disease progression from 62 to 45% 
in the treated group compared to an untreated 
group.13,14 

 To prevent glaucoma progression and to preserve 
vision, mean intraocular pressure should be decreased 
to a patient dependent target pressure. The target 
pressure depends on a number of factors, including 
age of patient, baseline IOP at which the damage 
occurred, structural damage (status of optic disc and 
RNFL), functional damage (assessed on perimetry) 
and the presence of additional risk factors for 
glaucomatous damage.15 

 The aim of glaucoma management is to preserve 
the visual functions and quality of life of the 
individual. Our objective should be not just to treat the 
intraocular pressure (IOP), but to treat the patient as a 
whole so as to provide maximum benefit with 
minimal side effects. 

 Medical treatment is the mainstay of glaucoma 
management, particularly of open angle glaucoma. A 
number of intraocular pressure-lowering agents are 
available which act either by decreasing aqueous 
secretion or by enhancing the aqueous outflow. The 

goal of medical treatment is to obtain 24 – hour IOP 
control with the minimum concentration and number 
of medications, as well as minimal local and systemic 
side effects.16 

 Latanoprost was well tolerated at all 
concentrations, with no differences between doses 
groups with respect any of the adverse events, 
including conjunctival hyperemia. There were two 
reports of iris darkening and 11 reports of eyelash 
growth, but there was no dose association for either of 
these events. Both are well recognized side effects of 
prostaglandin analog therapy.17 

 After a single topical dose of latanoprost 0.005%, 
IOP reduction is maximal within 8 to 12 hours and 
IOP remains below pretreatment level for at least 24 
hours. In 24-hour IOP measurements, latanoprost 
administered once a day in the evening induces a 
constant IOP reduction, although the hypotensive 
effect seems to be greatest during the day.16,17 

 In patients with glaucoma or ocular hypertension 
(IOP ≥ 21), a number of studies, between 1 and 12 
months’ treatment, report a reduced IOP level, from 
22% to 39%.18 

 Our study shows that topical 0.005% Latanoprost 
eye drops reduces the central corneal thickness as the 
mean CCT was observed (538  ± 1.87 μm vs. 534   ± 2.1 
2 μm) in 75% eyes in 8 weeks follow up. Similar results 
were found in other studies as Hatanaka M et al in a 
controlled trial have shown that Latanoprost 0.005% 
showed reduction of 0.86% in CCT from a baseline 
level of 548.57 μm ± 32.4 to 543.88 μm ± 35.6 after 8 
weeks of use.17 Xhong. Y, et al reported a decrease in 
CCT of 15.73 ± 3.25µm following latanoprost 
monotherapy.19 A statistically significant reduction in 
the mean CCT was observed in the latanoprost group 
(535.5   ±  37.9  μm vs. 530.1  ±  36.4 μm) in 77.10% eyes 
24 months following initiation of therapy by a similar 
study conducted by Kim HJ and Cho BJ.19 Another 
study conducted by Sen E, et al21 revealed a 1.9 ± 2.4% 
reduction in CCT from a mean baseline CCT value of 
559.5 ± 35.3 μm, 12 months following latanoprost 
therapy. 

 A meta – analysis of randomized clinical trials 
widely estimated the IOP reduction achieved by the 
most frequently prescribed glaucoma drugs and a 
placebo and pointed out that prostaglandin analogs 
are the most effective group for lowering IOP by mono 
therapy in primary open angle glaucoma (POAG) or 
ocular hypertensive patients, with a relative change of 
−31% (at peak) and −28% (at trough) for latanoprost. 



AKHUNZADA MOHAMMAD AFTAB, et al 

129      Vol. 31, No. 3, Jul – Sep, 2015 Pakistan Journal of Ophthalmology 

 After a long-term treatment, since latanoprost has 
no clinically significant effect on the permeability of 
the blood–aqueous barrier, IOP will return to 
pretreatment levels within a few weeks, indicating 
that latanoprost is safe for long-term treatments. 

 
CONCLUSION 

Our study concludes that topical 0.005% Latanoprost 
eye drops reduces the central corneal thickness as the 
mean CCT was observed (538  ± 1.87 μm vs. 534 ± 2.12 
μm) in 75% eyes in 8 weeks follow up, so latanoprost 
therapy requires careful monitoring while treating 
patients with primary open angle glaucoma. However 
this reduction in CCT was not ≥ 25 µm from base line 
readingwhich is not significant enough and hence did 
not have an effect on IOP reading using the Goldman 
Applanation tonometer. 

 
Author’s Affiliation 

Dr. Akhunzada Mohammad Aftab 
Junior Registrar, Eye “A” ward, Khyber Teaching 
Hospital, Peshawar 

Dr. Mubashir Rehman 
Medical Officer, Department of Ophthalmology, Lady 
Reading Hospital, Peshawar 

Dr. Sher Akbar Khan 
Consultant ophthalmologist, Medical Rehabilitation 
Complex, Charsaddah 

Dr. Farooq Khan 
Trainee Medical Officer, Department of 
Ophthalmology, Khyber Teaching Hospital, Peshawar 

Dr. Awais Rauf 
Trainee Medical Officer, Department of 
Ophthalmology, Khyber Teaching Hospital, Peshawar 

 
Role of Authors 

Dr. Akhunzada Mohammad Aftab 
Patients’ selection, data collection and data analysis. 

Dr. Mubashir Rehman 
Patients’ selection, data collection and data analysis. 

Dr. Sher Akbar Khan 
Patients’ selection, data collection and data analysis. 

Dr. Farooq Khan 
Literature search and references. 

Dr. Awais Rauf 
Literature search and references. 

REFRENCES 
1. Kumarasamy NA, Lam FS, Wang AL, Theoharides TC. 

Glaucoma: Current and developing concepts for 
inflammation, pathogenesis and treatment. Eur J 
Inflamm. 2006; 4: 129-37. 

2. Quiiqley HA, Broman AT. The number of people with 
glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 
2006; 90: 262-7. 

3. Dineen B, Bourne RR, Jadoon Z. Causes of blindness 
and visual impairment in Pakistan. Br J Ophthalmol. 
2007; 91: 1005-10. 

4. Hazin R, Hendrick AM, Kahook MY. Primary open-
angle glaucoma: Diagnostic approach and management. 
J Nati Med Assoc. 2009; 101: 46-50. 

5. Kanski JJ. Glaucoma. In: Kanski JJ Clinical 
Ophthalmology. A systemic approach 6th ed. 
Butterworth Heinemann Elsevier. 2007: 371-440. 

6. Izzotti A, Bagnis A, Saccà SC. The role of oxidative 
stress in glaucoma. Mutat Res. 2006; 612: 105-14. 

7. Theelen T, Meulendij CF, Geurts DE. Impact factors on 
intraocular pressure measurement in healthy subjects. 
Br J Ophthalmol. 2004; 88: 1510-1. 

8. Lodhi AA, Talpur KI, Khanzada MA. Latanoprost 
0.005% v/s timolol maleate 0.5% pressure lowering 
effect in primary open angle glaucoma. Pak J 
Ophthalmol. 2008; 24 (2): 68-72. 

9. Macleod SM, Clark R, Forrest J, Bain M, Bateman N, 
Azuara – Blanco A. A review of glaucoma treatment in 
Scotland 1994-2004. Eye, 2004; 22 (2): 251-5. 

10. Hoffmann EM, Lamparter J, Mirshahi A, Elflein H, 
Hoehn R, Wolfram C, Lorenz K, Adler M, Wild PS, 
Schulz A, Mathes B, Blettner M, Pfeiffer N. 
Distribution of central corneal thickness and its 
association with ocular parameters in a large central 
European cohort: the Gutenberg health study. PLoS 
One, 2013; 8 (8): 118-21. 

11. Channa R, Mir F, Shah MN, Ali A, Ahmad K. Central 
corneal thickness of Pakistani adults. J Pak Med Assoc. 
2009; 59 (4): 225-8. 

12. Patel SS, Spencer CM. Latanoprost. A review of its 
pharmacological properties, and tolerability in the 
management of primary open-angle glaucoma and 
ocular hypertension. Drugs Aging, 1996; 9: 363-78. 

13. Rulo AH, Greve EL, Hoyng PF. Additive ocular 
hypotensive effect of latanoprost and acetazolamide: A 
short-term study in patients with elevated intraocular 
pressure. Ophthalmology, 1997; 104: 1503-7. 

14. Novack GD, O'Donnell MJ, Molloy DW. New 
glaucoma medications in the geriatric population: 
Efficacy and safety. J Am Geriatr Soc. 2002; 50: 956-62.  

15. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, 
Autelitano A. Effect of timolol, latanoprost, and 
dorzolamide on circadian IOP in glaucoma or ocular 
hypertension. Invest Ophthalmol Vis Sci. 2000; 41: 2566-
73. 

16. Johnstone MA. Hypertrichosis and increased 
pigmentation of eyelashes and adjacent hair in the 

http://www.ncbi.nlm.nih.gov/pubmed/?term=Hoffmann%20EM%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Lamparter%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Mirshahi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Elflein%20H%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Hoehn%20R%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Wolfram%20C%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Lorenz%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Adler%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Wild%20PS%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Schulz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Mathes%20B%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Blettner%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Pfeiffer%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23936291
http://www.ncbi.nlm.nih.gov/pubmed/23936291
http://www.ncbi.nlm.nih.gov/pubmed/23936291
http://www.ncbi.nlm.nih.gov/pubmed/23936291
http://www.ncbi.nlm.nih.gov/pubmed/?term=Channa%20R%5BAuthor%5D&cauthor=true&cauthor_uid=19402284
http://www.ncbi.nlm.nih.gov/pubmed/?term=Mir%20F%5BAuthor%5D&cauthor=true&cauthor_uid=19402284
http://www.ncbi.nlm.nih.gov/pubmed/?term=Shah%20MN%5BAuthor%5D&cauthor=true&cauthor_uid=19402284
http://www.ncbi.nlm.nih.gov/pubmed/?term=Ali%20A%5BAuthor%5D&cauthor=true&cauthor_uid=19402284
http://www.ncbi.nlm.nih.gov/pubmed/?term=Ahmad%20K%5BAuthor%5D&cauthor=true&cauthor_uid=19402284
http://www.ncbi.nlm.nih.gov/pubmed/19402284


EFFECT OF TOPICAL LATANOPROST 0.005% DROPS ON CENTRAL CORNEAL THICKNESS IN PATIENTS WITH POAG 

Pakistan Journal of Ophthalmology Vol. 31, No. 3, Jul – Sep, 2015      130 

region of the ipsilateral eyelids of patients treated with 
unilateral topical latanoprost. Am J Ophthalmol. 1997; 
124: 544-7. 

17. Hatanaka M, Vessani RM, Elias IR, Morita C, Susanna 
R, Jr. The effect of prostaglandin analogs and 
prostamide on central corneal thickness. J Ocul 
Pharmacol Ther. 2009; 25 (1): 51-3. 

18. Watson P, Stjernschantz J. A six – month, randomized, 
double – masked study comparing latanoprost with 
timolol in open – angle glaucoma and ocular 
hypertension. Ophthalmology, 1996; 103: 126-37. 

19. Xhong Y, Shen X, Yu J, Tan H, Cheng Y. The 
comparison of the effects of latanoprost, travoprost and 
bimetaprost on central corneal thickness. Cornea, 2011; 
30 (8): 861-4. 

20. Kim HJ, Cho BJ. Long term effect of latanoprost on 
central corneal thickness in normal tension glaucoma. J 
Ocul Pharmacol Ther. 2011; 27 (1): 73-6. 

21. Sen E, Nalcacioqlu P, Yazici A, Aksakal FN, Altonok 
A, Tuna T, Koklu G. Comparison of the effects of 
latanoprost and bimetaprost on central corneal 
thickness. J Glaucoma, 2008; 17 (5): 398-402.